|
Product class:
|
Medicinal product with marketing authorization
|
|
Medicinal product class:
|
Veterinary medicine
|
|
Name of medicinal product:
|
Oncept IL-2
|
|
Active substances:
|
|
|
ATC code:
|
QL03AX90
|
|
Dosage form:
|
lyophilisate and solvent for suspension for injection
|
|
Strength:
|
|
|
Legal status for supply*:
|
Subject to medicinal prescription
|
|
Summary of product characteristics (SPC):
|
|
|
Package information leaflet (PIL):
|
EST
|
|
Labelling:
|
|
|
Indication:
|
Immunotherapy to be used in addition to surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement in order to reduce the risk of relapse and to increase the time to relapse (local recurrence or metastasis). This was demonstrated in a field trial over a period of 2 years.
|
|
Safety features:
|
No
|
|
Marketing authorization holder:
|
Boehringer Ingelheim Vetmedica GmbH
|
|
Marketing authorization number:
|
EU/2/13/150
|
|
Marketing authorization issued on:
|
May 7, 2013
|
|
Marketing authorization expires on:
|
Unlimited
|
|
Marketing authorization procedure type:
|
Centralised
|
|
Assessment report:
|
|
|
Package code
|
Name of medicinal product
|
Dosage form
|
Package
|
Legal status
|
Reimbursements
|
Reference price
|
Last imported
|
PƤritolumaa
|
Additional information
|
|
1619164
|
Oncept IL-2
|
lyophilisate and solvent for suspension for injection
|
1annus 6TK
|
Prescription
|
|
|
|
|
lahusti 1 ml
|
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription
You can download Acrobat Reader fromhere